Microglia, the brain's resident immune cells, behave differently depending on whether frontotemporal dementia (FTD) arises from a specific genetic mutation or occurs without a known genetic cause, according to a laboratory study published in Stem Cell Reports. Researchers at the University of Eastern Finland, led by Professor Annakaisa Haapasalo, used induced pluripotent stem cell (iPSC) technology to grow microglia from three groups: patients carrying the C9orf72 hexanucleotide repeat expansion (C9-HRE), the most common known genetic cause of FTD; patients with sporadic FTD, meaning no identified causative mutation; and healthy controls. The team, whose lead author is Hannah Rostalski, then compared the cells' gene expression, phagocytic behavior and other functional traits.

The study found that gene expression changes in C9-HRE microglia were, in the researchers' own words, "fairly modest" compared with controls. Microglia from sporadic FTD patients, by contrast, showed a gene expression profile that differed significantly from both the C9-HRE cells and the healthy controls. The researchers also reported increased phagocytic activity, the process by which microglia engulf material including synapses, in patient-derived cells. Haapasalo said that increased phagocytic activity could lead to greater loss of synapses and, potentially, impaired communication between neurons, a hypothesis the team says it is now investigating further.

The work builds on the same laboratory's earlier bioRxiv-posted findings that C9orf72 repeat expansion carrying microglia showed increased phagocytic activity alongside fewer autophagosomal-lysosomal vesicles, structures involved in clearing cellular waste. Taken together, the two genetic and sporadic patient groups did not simply show a shared, generic FTD immune signature; instead, the pattern of change tracked with how the disease arose. The authors say the divergence argues for studying microglial contributions separately in genetically defined and sporadic forms of the disease, rather than treating FTD as immunologically uniform.

The research adds a cellular, immune-focused strand to a busy field. Other FTD research areas have focused on protein aggregation and RNA splicing defects inside neurons themselves; this study instead asks what the brain's support and clearance cells are doing during disease, and whether that differs by cause. The authors themselves frame the phagocytosis-synapse loss link as a hypothesis under active investigation, not a settled mechanism.